Passage Bio Inc (PASG) Stock Price, Quote & News

Company Profile

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metach...

Industry: Biotechnology

Sector: Healthcare

Phone: 267 866 0311

Website: www.passagebio.com

Address:

One Commerce Square, 2005 Market Street 39th Floor, Philadelphia, United States

signaljumper Dec. 9 at 9:59 AM

$PASG a Close above 10.42 and WE have next target of 16.87$

0 · Reply

signaljumper Dec. 8 at 3:27 PM

$PASG 31M float Low float biotech gem ready to Run

0 · Reply

signaljumper Dec. 8 at 3:07 PM

$PASG loading at this Level

0 · Reply

Ventureville Nov. 21 at 5:46 PM

Small-cap immuno-oncology is waking up FAST: $BIOV (DPX + survivin, insider cash, tiny float) $IMV old believers know the tech $CADL (NeoTCR) $GRTS (Gritstone gorilla) $PASG (precision) When one rips they all get discovered again. Loading season 🚀

0 · Reply

Davb1231 Nov. 15 at 2:53 PM

$PASG

0 · Reply

StockScanners Nov. 15 at 4:32 AM

$PASG reached 9.03

0 · Reply

signaljumper Nov. 13 at 6:20 AM

$PASG the main upcoming catalyst for PASG is the H2 2025 interim clinical data update for PBFT02, followed by a potential regulatory agreement for a pivotal trial in early 2026 Time to load

0 · Reply

StockScanners Nov. 13 at 3:06 AM

$PASG keep watch if this holds above 8.50

0 · Reply

Godwins26 Nov. 12 at 10:00 PM

Watchlist for today 😊 $NVVE is on a after hours run higher right now!!!!😊 $PASG $CLBT $ABEO $CMBM

0 · Reply

signaljumper Nov. 12 at 7:55 PM

$PASG a Close above 10 bucks give the Stock a lot of space to move north and we are finished with the bottom First target 12 bucks

0 · Reply

Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights

Nov 5, 2025, 7:00 AM EST - 5 weeks ago

Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Oct 14, 2025, 7:00 AM EDT - 2 months ago

Passage Bio to Participate in Chardan's 9th Annual Genetic Medicines Conference

Aug 28, 2025, 7:00 AM EDT - 3 months ago

Passage Bio to Participate in H.C. Wainwright 27th Annual Global Investment Conference

Aug 12, 2025, 7:00 AM EDT - 4 months ago

Passage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business Highlights

Jul 10, 2025, 7:00 AM EDT - 5 months ago

Passage Bio Announces 1-for-20 Reverse Stock Split

Jun 23, 2025, 7:00 AM EDT - 6 months ago

Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update

May 13, 2025, 7:00 AM EDT - 7 months ago

Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights

Mar 4, 2025, 7:00 AM EST - 10 months ago

Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights

Feb 26, 2025, 7:00 AM EST - 10 months ago

Passage Bio to Participate in Upcoming Investor Conferences

Jan 10, 2025, 7:00 AM EST - 11 months ago

Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates

Nov 6, 2024, 7:00 AM EST - 1 year ago

Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference

Oct 24, 2024, 7:00 AM EDT - 1 year ago

Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference

Sep 23, 2024, 7:00 AM EDT - 1 year ago

Passage Bio to Present at Chardan's 8th Annual Genetic Medicines Conference

Sep 10, 2024, 7:52 AM EDT - 1 year ago

Passage Bio Welcomes Tom Kassberg to Board of Directors

Aug 30, 2024, 7:00 AM EDT - 1 year ago

Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 8, 2024, 7:00 AM EDT - 1 year ago

Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights

Aug 1, 2024, 7:00 AM EDT - 1 year ago

Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration

Jul 16, 2024, 7:00 AM EDT - 1 year ago

Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients

Jun 5, 2024, 7:30 AM EDT - 1 year ago

Passage Bio to Present at Goldman Sachs 45th Annual Global Healthcare Conference

May 21, 2024, 8:00 AM EDT - 1 year ago

Passage Bio Announces Recipient of Third Annual Tachi Yamada Scholarship Award

May 14, 2024, 7:00 AM EDT - 1 year ago

Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights

Apr 22, 2024, 7:00 AM EDT - 1 year ago

Passage Bio to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Mar 4, 2024, 7:00 AM EST - 1 year ago

Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights

Feb 27, 2024, 7:00 AM EST - 1 year ago

Passage Bio to Participate in Upcoming Investor Conferences

Jan 31, 2024, 7:30 AM EST - 2 years ago

Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Dec 20, 2023, 7:00 AM EST - 2 years ago

Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities

Nov 17, 2023, 4:30 PM EST - 2 years ago

Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Nov 13, 2023, 7:00 AM EST - 2 years ago

Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights

Oct 30, 2023, 7:00 AM EDT - 2 years ago

Passage Bio to Present at Guggenheim's 5th Annual Inflammation, Neurology & Immunology Conference

Oct 20, 2023, 4:30 PM EDT - 2 years ago

Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 25, 2023, 7:00 AM EDT - 2 years ago

Passage Bio to Present at Chardan's 7th Annual Genetic Medicines Conference

Aug 7, 2023, 7:15 AM EDT - 2 years ago

Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights

Aug 7, 2023, 7:00 AM EDT - 2 years ago

Passage Bio Announces Promising Interim Clinical Data from First Eight Patients with GM1 Gangliosidosis in Imagine-1 Study

Jul 31, 2023, 7:00 AM EDT - 2 years ago

Passage Bio Welcomes Dolan Sondhi, Ph.D. to Board Of Directors

Jun 5, 2023, 7:00 AM EDT - 2 years ago

Passage Bio to Present at Goldman Sachs 44th Annual Global Healthcare Conference

May 11, 2023, 7:00 AM EDT - 2 years ago

Passage Bio Reports First Quarter 2023 Financial Results and Provides Recent Business Highlights

Apr 21, 2023, 4:01 PM EDT - 2 years ago

Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 17, 2023, 7:00 AM EDT - 2 years ago

Passage Bio to Present at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Mar 27, 2023, 7:00 AM EDT - 2 years ago

Passage Bio to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days

Mar 6, 2023, 1:07 PM EST - 3 years ago

Passage Bio, Inc. (PASG) Q4 2022 Earnings Call Transcript

Mar 6, 2023, 7:00 AM EST - 3 years ago

Passage Bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Recent Business Highlights

Feb 28, 2023, 11:39 PM EST - 3 years ago

Passage Bio Undervalued On Price, Long-Term Gene Therapy Prospects

Feb 28, 2023, 7:00 AM EST - 3 years ago

Passage Bio to Present at Cowen 43rd Annual Health Care Conference

Feb 27, 2023, 7:00 AM EST - 3 years ago

Passage Bio to Report Fourth Quarter and Full-Year 2022 Financial Results on March 6, 2023

Feb 24, 2023, 7:00 AM EST - 3 years ago

Passage Bio Presents Additional Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium™ 2023

Feb 15, 2023, 7:00 AM EST - 3 years ago

Passage Bio to Present Updated Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium™ 2023

Dec 14, 2022, 7:00 AM EST - 3 years ago

Passage Bio Announces Positive Interim Clinical Data from First Six Patients with GM1 Gangliosidosis in Imagine-1 Study

Nov 10, 2022, 10:26 AM EST - 3 years ago

Passage Bio, Inc. (PASG) Q3 2022 Earnings Call Transcript

Nov 10, 2022, 7:00 AM EST - 3 years ago

Passage Bio Reports Third Quarter 2022 Financial Results and Provides Business Updates

signaljumper Dec. 9 at 9:59 AM

$PASG a Close above 10.42 and WE have next target of 16.87$

0 · Reply

signaljumper Dec. 8 at 3:27 PM

$PASG 31M float Low float biotech gem ready to Run

0 · Reply

signaljumper Dec. 8 at 3:07 PM

$PASG loading at this Level

0 · Reply

Ventureville Nov. 21 at 5:46 PM

0 · Reply

Davb1231 Nov. 15 at 2:53 PM

$PASG

0 · Reply

StockScanners Nov. 15 at 4:32 AM

$PASG reached 9.03

0 · Reply

signaljumper Nov. 13 at 6:20 AM

$PASG the main upcoming catalyst for PASG is the H2 2025 interim clinical data update for PBFT02, followed by a potential regulatory agreement for a pivotal trial in early 2026 Time to load

0 · Reply

StockScanners Nov. 13 at 3:06 AM

$PASG keep watch if this holds above 8.50

0 · Reply

Godwins26 Nov. 12 at 10:00 PM

Watchlist for today 😊 $NVVE is on a after hours run higher right now!!!!😊 $PASG $CLBT $ABEO $CMBM

0 · Reply

signaljumper Nov. 12 at 7:55 PM

$PASG a Close above 10 bucks give the Stock a lot of space to move north and we are finished with the bottom First target 12 bucks

0 · Reply

BDE_Worldwide Nov. 12 at 7:26 PM

$PASG these low floaters can move quick… shorts forced to cover…

0 · Reply

wrengler4 Nov. 12 at 2:59 PM

$PASG wow and this also will happen according to JarvisFlow:

0 · Reply

anachartanalyst Nov. 12 at 1:02 PM

$PASG https://anachart.com/wp-content/uploads/ana_temp/1762952510_soc-img.jpg

0 · Reply

JarvisFlow Nov. 12 at 12:33 PM

Chardan Capital has adjusted their stance on Passage Bio ( $PASG ), setting the rating to Buy with a target price of 6 → 21.

0 · Reply

BillionerOfKing Nov. 11 at 12:08 PM

$PASG Current Stock Price: $6.70 Contracts to trade: $7.5 PASG Dec 19 2025 Call Entry: $0.05 Exit: $0.09 ROI: 94% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Chasen_Gains Nov. 3 at 1:28 PM

$PSTV Be careful with these low penny stocks, everyone has to be able to reflect on $PASG last year when it was near the same level and had over 7 analysts saying it was a 6.00 per share equity. Well about 3-4 months ago it finally hit 6.00, but that was after it did an RS. If I buy this I would only hold til it hits 5% up then sell it. Might not be glamorous but it keeps a person from bag holding and getting their capital stuck for a while. Bring the hate

0 · Reply

JoshThe3rd Oct. 22 at 1:00 AM

$PASG ALEC fail. Passage will probably go under 7.00. But the good news is that a fund called Lynx1 still believes in the therapy and will probably do an offering once the company announces FDA guidance for pivotal trial. As you have seen with QRNX these low floats who announce good offerings w good financiers tend to pump 2x-3x on news. QNRX offering at 8.00 pumped to 40.00 intraday.

0 · Reply

JoshThe3rd Oct. 20 at 2:43 PM

$PASG I think this has 1 last dip in it. Next potential mover catalysts are ALEC FTD-GRN data in November and 1H 2026 registrational pathway guidance update.

0 · Reply

blankstocker Oct. 17 at 1:45 PM

$PASG Spread on this is getting larger.

0 · Reply

petemal Oct. 10 at 7:21 PM

$PASG this is the one

0 · Reply

petemal Oct. 10 at 7:18 PM

$QNRX $PASG small float big money

0 · Reply

petemal Oct. 10 at 7:17 PM

$SPRB look at $PASG small float big money

0 · Reply

Market Cap	31.53M
Revenue (ttm)	0.00
Net Income (ttm)	-64.77M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	40,700
Avg Vol	41,308
Day's Range	N/A - N/A
Shares Out	3.18M
Stochastic %K	93%
Beta	1.86
Analysts	Strong Sell
Price Target	$32.50